December 1, 2014

homepage

March 31, 2015

X-Chem and Navitor Pharmaceuticals Enter into License Agreement on Novel Small Molecules Targeting mTORC1 Activation

WALTHAM & CAMBRIDGE, Mass. – March 30, 2015 –X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive […]

Continue Reading
January 9, 2015

X-Chem Announces Collaboration with Janssen and Johnson & Johnson Innovation to Advance Novel Candidates to Treat Inflammatory Diseases

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc. (“X-Chem”), a privately held biotechnology company applying its cutting-edge drug discovery platform to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration, which is being facilitated […]

Continue Reading
January 9, 2015

X-Chem Promotes Diala Ezzeddine to Executive Vice President and Chief Business Officer

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that Diala Ezzeddine, Ph.D., has been promoted to executive vice president and chief business officer, effective December 6, 2014.

Continue Reading